It is, therefore, not unexpected that loss of AAT via stool during gastrointestinal GVHD is predictive of poor response to corticosteroid therapy [23], and that AAT infusions improve clinical outcomes in patients with acute steroid-refractory GVHD [24,25,26,27]. The gene discussed is SERPINA1; the disease is graft versus host disease.